Last Updated on February 4, 2021 by The Health Master
Dr Reddy’s Laboratories Ltd announced the launch of vigabatrin tablets USP, 500 mg, a therapeutic equivalent generic version of Sabril (vigabatrin) tablets, USP, approved by the US Food and Drug Administration (USFDA).
“We are pleased that this product has been designated as a competitive generic therapy (CGT) by the FDA,” says Marc Kikuchi, chief executive officer, North America Generics, Dr. Reddy’s Laboratories.
The Sabril brand and generic had US sales of approximately US$ 141 million MAT for the most recent twelve months ending in December 2020 according to IMS Health.
Dr Reddy’s vigabatrin tablets, USP are available in 500 mg tablets in a bottle count size of 100.
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here